KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

KALV 11.26.2024

Full Press ReleaseSEC FilingsOur KALV Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
  • 01.08.2025 - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.07.2025 - Stacy Ku

Recent Filings

  • 01.16.2025 - S-8 Securities to be offered to employees in employee benefit plans
  • 12.16.2024 - 8-K Current report
  • 12.16.2024 - EX-99.1 EX-99.1

CAMBRIDGE, Mass.&SALISBURY, England--(BUSINESS WIRE)--Nov. 26, 2024--KalVista Pharmaceuticals, Inc.(NASDAQ: KALV), today announced thatLaurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately.Dr. Reidbrings more than three decades of experience with a track record of leadership and company-building success.

“I am pleased to welcomeDr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors,” saidBen Palleiko, Chief Executive Officer ofKalVista. “His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization.”

“I am excited to join the KalVista Board at this transformational time in the Company’s journey,” saidDr. Reid. “I believe sebetralstat has the potential to significantly improve the lives of people living with hereditary angioedema. I look forward to working with the team on the Company’s transition to a commercial organization and supporting its long-term growth.”

Dr. Reidwas the CEO ofDecibel Therapeuticsprior to its acquisition by Regeneron Pharmaceuticals inSeptember 2023. Previously,Dr. Reidserved as an entrepreneur in residence atThird Rock Ventures, where he focused on novel drug discovery opportunities. Before Third Rock,Dr. Reidwas Chief Executive Officer ofWarp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018. He also served as Chief Business Officer of Alnylam Pharmaceuticals andEnsemble Therapeuticsand held senior leadership roles atMillennium Pharmaceuticals.Dr. Reidcurrently serves as the chair of the board of Broken String Biosciences, is a board member ofGaruda Therapeutics and The Possible Zoneand serves as a board advisor to Life Science Cares andMount Auburn Hospital.

AboutKalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet needs. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date ofJune 17, 2025. In addition, we have completed Marketing Authorization Application (MAA) submissions for sebetralstat to theEuropean Medicines Agencyand theUnited Kingdom,Switzerland,Australia, andSingapore. For more information, please visitwww.kalvista.comor follow us on social media at@KalVistaandLinkedIn.

About Sebetralstat

Discovered and developed entirely byKalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). Our initial goal is to deliver sebetralstat as the first oral, on-demand treatment forHAE inpeople aged 12 years and older. In addition, we are studying the potential of sebetralstat for the on-demand treatment ofHAE inchildren aged 2 to 11 years. We believe that, if approved, sebetralstat has the potential to become the foundational therapy for HAE disease management globally.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of theU.S.Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with theSecurities and Exchange Commission, including in our annual report on Form 10-K for the year endedApril 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with theSecurities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241126695350/en/

Media:Jenn SnyderVice President, Corporate Affairs(857) 356-0479jennifer.snyder@kalvista.com

Investors:Ryan BakerHead, Investor Relations(617) 771-5001ryan.baker@kalvista.com

Source:KalVista Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com